Table 4.
Relationship between the levels of microRNAs in preoperative plasma and clinicopathological characteristics.
| Target MicroRNAs | ||||||||
|---|---|---|---|---|---|---|---|---|
| MIR21 | MIR29a | MIR92a | ||||||
| −∆Ct value ‡ | p-value | −∆Ct value ‡ | p-value | −∆Ct value‡ | p-value | |||
| Gender | Male | 17 (38.6) | −2.54 [−3.91–0.14) | 0.63 | −3.86 (−5.63–−1.3) | 0.44 | −1.79 (−2.95–−0.59) | 0.98 |
| Female | 27 (61.4) | −2.61 (−4.31–0.07) | −3.76 (−1.14–−6.33) | −1.70 (−2.78–−0.95) | ||||
| Age | ≥75 | 14 (31.8) | −2.74 (−3.91–0.07) | 0.22 | −3.58 (−5.42–−2.32) | 0.74 | −1.66 (−2.36–−0.92) | 0.17 |
| <75 | 30 (68.2) | −2.86 (−4.31–0.14) | −4.03 (−6.33–−1.14) | −1.85 (−2.95–−0.59) | ||||
| BMI | ≥22 | 22 (50.0) | −2.62 (−4.31–0.14) | 0.92 | −4.08 (−6.33–−1.35) | 0.21 | −1.80 (−2.95–−0.59) | 0.34 |
| <22 | 22 (40.0) | −2.57 (−3.98–−0.93) | −3.61 (−5.97–−1.14) | −1.73 (−2.36–−0.90) | ||||
| Tumor location | Colon | 27 (61.4) | −2.52 (−3.91–0.07) | 0.71 | −3.92 (−6.33–−1.14) | 0.67 | −1.81 (−2.95–−0.90) | 0.70 |
| Rectum | 17 (38.6) | −2.61 (−4.31–0.14) | −3.76 (−5.97–−1.35) | −1.75 (−2.57–−0.59) | ||||
| Right side | 17 (38.6) | −2.48 (−3.91–0.07) | 0.17 | −3.38 (−6.13–−1.14) | 0.16 | −1.66 (−2.36–−0.90) | 0.23 | |
| Left side | 27 (61.4) | −2.84 (−4.31–0.14) | −4.01 (−6.33–−1.35) | −1.83 (−2.95–−0.59) | ||||
| Preoperative CEA | Elevated | 18 (40.1) | −2.52 (−4.31–−0.93) | 0.51 | −3.66 (−6.13–−1.14) | 0.51 | −1.78 (−2.57–−0.59) | 0.74 |
| Normal | 26 (59.1) | −2.86 (−3.98–0.14) | −3.86 (−6.33–−1.35) | −1.77 (−2.95–−0.99) | ||||
| Preoperative CA19-9 | Elevated | 12 (27.3) | −2.45 (−3.54–0.14) | 0.07† | −3.66 (−4.76–−1.14) | 0.10 | −1.81 (−2.95–−0.99) | 0.58 |
| Normal | 32 (72.7) | −2.77 (−4.31–0.07) | −3.86 (−6.33–−1.35) | −1.77 (−2.95–−0.95) | ||||
| Maximum tumor diameter | ≥45 | 22 (50.0) | −2.50 (−3.61–0.14) | 0.07† | −3.68 (−5.32–−1.30) | 0.046* | −1.77 (−2.95–−0.59) | 0.30 |
| <45 | 22 (50.0) | −2.99 (−4.31–0.07) | −4.08 (−6.33–−1.35) | −1.70 (−2.78–−1.38) | ||||
| Pathological T stage § |
T3 + T4 | 33 (75.0) | −2.52 (−4.31–0.14) | 0.14 | −3.70 (−6.13–−1.14) | 0.19 | −1.75 (−2.95–−0.59) | 0.64 |
| T1 + T2 | 11 (25.0) | −2.99 (−3.98–−1.46) | −4.03 (−6.33–−2.32) | −1.79 (−2.78–−1.39) | ||||
| Pathological N stage § |
Present | 20 (45.4) | −2.53 (−3.97–0.14) | 0.22 | −3.70 (−5.56–−1.14) | 0.09† | −1.77 (−2.33–−0.59) | 0.39 |
| Absent | 24 (54.5) | −2.77 (−4.31–0.07) | −4.03 (−6.33–−1.61) | −1.76 (−2.95–−0.95) | ||||
| Pathological Stage § |
III + IV | 22 (50.0) | −2.52 (−3.97–0.14) | 0.21 | −3.66 (−5.56–−1.14) | 0.02* | −1.77 (−2.33–−0.59) | 0.24 |
| I + II | 22 (50.0) | −2.90 (−4.31–0.07) | −4.09 (−6.33–−2.32) | −1.76 (−2.95–−1.07) | ||||
| Histological differentiation ¶ | Poorly | 6 (13.6) | −2.70 (−3.21–0.14) | 0.24 | −3.66 (−3.86–−1.30) | 0.22 | −1.98 (−2.33–−0.92) | 0.56 |
| Well and moderately | 38 (86.4) | −2.58 (−4.31–0.07) | −4.03 (−6.33–−1.14) | −1.73 (−2.95–−0.59) | ||||
| Lymphatic invasion ¶ |
High | 13 (29.5) | −1.92 (−3.98–0.14) | 0.05† | −3.58 (−5.97–−1.14) | 0.05† | −1.75 (−2.29–−0.9) | 0.61 |
| Mild | 31 (70.4) | −2.69 (−4.31–0.07) | −4.03 (−6.33–−1.61) | −1.81 (−2.95–−0.59) | ||||
| Venous invasion ¶ | High | 15 (34.1) | −2.43 (−3.98–−1.20) | 0.85 | −4.14 (−5.97–−1.30) | 0.43 | −1.75 (−2.26–−0.59) | 0.10 |
| Mild | 29 (65.9) | −2.84 (−4.31–0.14) | −3.66 (−6.33–−1.14) | −1.81 (−2.95–−0.92) | ||||
| Perineural invasion ¶ | Positive | 25 (56.8) | −2.48 (−3.61–0.14) | 0.01* | −3.66 (−6.13–−1.14) | 0.26 | −1.81 (−2.95–−0.59) | 0.58 |
| Negative | 19 (43.2) | −3.08 (−4.31–−1.49) | −4.03 (−6.33–−1.35) | −1.69 (−2.78–−1.39) | ||||
CEA: Carcinoembryonic antigen level, normal upper limit at 5 ng/mL, CA19-9: Carbohydrate antigen 19-9 level, normal upper limit at 37 ng/mL, ‡: −∆Ct value = −(Ct value (target MIR)–Ct value (internal control MIR16)), §: UICC TNM classification (the 8th edition), ¶: the Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma: the 3rd English Edition (†: p < 0.1 *: p < 0.05).